| Business Summary | | Lorus
Therapeutic
Inc.
is
a
biopharmaceutical
company
focused
on
the
research
and
development
of
cancer
therapies.
Lorus'
goal
is
to
capitalize
on
its
research,
pre-clinical,
clinical
and
regulatory
expertise
by
developing
new
drug
candidates
that
can
be
used,
either
alone,
or
in
combination,
to
successfully
manage
cancer.
Through
its
own
discovery
efforts
and
an
active
in-licensing
and
acquisition
program,
Lorus
is
building
a
portfolio
of
promising
anti-cancer
drugs.
Included
in
the
Company's
portfolio
are
its
two
leading
antisense
therapy
candidates,
GTI-2040
and
GTI-2501,
and
VIRULIZIN,
a
potential
new
drug
functioning
as
a
biologic
response
modifier
for
the
treatment
of
cancer.
The
Company
also
has
a
license
from
Ion
Pharmaceuticals,
Inc.
for
clotrimazole
(CLT),
a
molecule
with
anti-angiogenic
and
anti-proliferative
properties,
and
CLT-related
analogues,
for
anti-cancer
indications
as
well
as
Kaposi's
Sarcoma
and
actinic
keratosis. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Lorus
Therapeutics
Inc.
is
a
biopharmaceutical
company
engaged
in
the
research
and
development
of
cancer
therapies.
LORFF
is
developing
new
drug
candidates
that
can
be
used
to
successfully
manage
cancer.
For
the
nine
months
ended
2/28/01,
the
Company
reported
no
revenues.
Net
loss
totaled
C$9.1
million,
up
from
C$3.4
million.
Higher
loss
reflects
increased
R&D
expenses
due
to
the
amortization
of
acquired
R&D
assets
and
higher
general
and
administrative
expenses. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY1999 Pay | |
| Peter Campbell Interim
Chairman | -- | Jim Wright, Ph.D. Pres
and CSO | -- | Guy Ely, M.D. VP,
Drug Devel. | $233K | Aiping Young, M.D., Ph.D. VP,
Research | -- | James Parsons VP
of Fin. and Admin., CFO | -- | Dollar amounts are as of 31-May-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|